Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Niagen Bioscience, Inc. (NAGE)

NCM · Biotechnology

$3.29+0.06 (+1.86%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$262.0M
P/E (TTM)
15.67
EPS
$0.21
Div Yield
52W Range
$3.12–$11.29
Beta
2.08

Company overview

Next earnings: 2026-08-04(7d)

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Peers in Biotechnology

All in industry →

Recent press releases

Niagen Bioscience, Inc. has not issued a press release in this window.

SEC filings

All filings →

Niagen Bioscience, Inc. has not filed an SEC document in this window.

Niagen Bioscience, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
3,286,498 sh-18.3%
4,075,709 sh+2.5%
491,962 sh-37.8%
1,294,863 sh-0.0%
561,110 sh-27.5%
1,091,039 sh-0.1%
346,545 sh-36.5%

People at Niagen Bioscience, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI $5.1M
06/25
$22.7M
NI $3.6M
09/25
$34.0M
NI $4.6M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.05
Prior: $0.04
Revenue sparkline